Jun 2, 2009 | Med Ad News
Pfizer Introduces New Treatment And Support Plan For Patients With Overactive Bladder
Jun 2, 2009 - Pfizer Inc announced today that Toviaz extended release tablets and the YourWay plan , a comprehensive, customizable support plan for overactive bladder patients, are available in the United States.
Bladder Urothelial Cells From Patients With Interstitial Cystitis...
UroToday.com - The presence of muscarinic receptors on bladder urothelial cells suggests BUC may be a target for antimuscarinics.
Pfizer's prescription for patent loss: new drug
Drug giant ceases marketing for $1.2 billion Detrol as it launches Toviaz, which treats the same condition.
Randomized, Placebo-Controlled, Double-Blind, Crossover Study ...
Main Category: Urology / Nephrology Also Included In: Cardiovascular / Cardiology ; Infectious Diseases / Bacteria / Viruses ; Clinical Trials / Drug Trials Article Date: 23 Feb 2009 - 1:00 PST UroToday.com - ...
Journal Watch: New Drug for Overactive Bladder
* Adverse effects are attributable to its anticholinergic properties. Fesoterodine fumarate has been approved by the Food and Drug Administration for the treatment of overactive bladder in adults.
Long-Term Efficacy And Safety Of Tolterodine In Children With Neurogenic Detrusor Overactivity
Main Category: Urology / Nephrology Also Included In: Pediatrics / Children's Health Article Date: 15 Jan 2009 UroToday.com - In a recent journal article, Dr.
Drug adherence poor in women with urinary trouble
The odds are high that a woman who is prescribed an "anticholinergic" drug to relieve urinary incontinence or other lower urinary tract symptom will discontinue the medication not long after starting it, a ...